Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: PIM
Latest Price: 13.50p  (-1.82% Descending)
52-week High: 35.25p
52-week Low: 13.50p
Market Cap: 6.81M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Plant Impact
www.plantimpact.com

Plant Impact's range of crop nutrition products focus on crop enhancement. They improve crop performance and crop health giving growers increased marketable yields, better quality and longer shelf life with reduced environmental impact.

Pdf

Plant Impact gets new CEO

9th Aug 2011, 7:52 am by Jon Mainwaring Plant Impact develops and sells product designed to improve the health of crops

Environmental technology business Plant Impact (LON:PIM) has announced that John Brubaker will be its next chief executive officer.

Brubaker will become CEO on 1 September and he succeeds Peter Blezard, who has resigned.

Until recently, Brubaker was the global head of business development for Tokyo-based Arysta LifeScience Corporation – a 9.1 per cent shareholder in Plant Impact and a commercial partner of the firm.

Prior to Arysta, Brubaker was the director of business development at R4 Global Solutions – a San Francisco-based technology start up that has since been acquired by Verisign.

“On behalf of the board of directors, I am delighted that the company has secured the commitment of such a high calibre individual to lead it as the CEO,” said David Jones, Plant Impact’s chairman. “Plant Impact is expanding its customer base internationally while continuing to invest in innovative new technologies, and further developing its relationships with strategic partners. For this new and exciting phase of the company’s growth, the board is confident that John will bring the right blend of skill and experience to Plant Impact.”

Plant Impact develops and sells product designed to improve the health of crops.

At the start of July, the firm reported that its turnover for the year to the end of March increased to £1.8 million from £1.4 million in 2010, although pre-tax losses widened to £1.9 million (2010: £1.7 million) due to increased R&D spending and a delay in its BugOil product getting regulatory clearance.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.